About Inviragen
Inviragen is a Healthcare company based in Fort Collins (United States) founded in 2005, and was acquired by Takeda in May 2013. Vaccines for infectious diseases including dengue and influenza were developed. Inviragen has raised $15.31 million across 11 funding rounds from investors including NIH, Takeda Pharmaceuticals and HHS. Inviragen has completed 1 acquisition, including SingVax. Inviragen offers products and services including Keluaran HK and Data HK. Its focus areas include Life Sciences, Immunotherapy, Vaccine and Prophylactic. Its legal entity is INVIRAGEN, INC. Its competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines; 3 of its 3 listed competitors have raised funding.
Company details
Inviragen was founded in 2005 in Fort Collins, United States, focusing on the biotechnology sector. Vaccines were developed there to address infectious diseases such as dengue, hand-foot-and-mouth disease, chikungunya, Japanese encephalitis, influenza, and a combined plaguesmallpox option for biodefense purposes. The company was acquired by Takeda in 2013 for an initial 35 million, with potential additional payments up to 215 million based on development progress and commercial milestones.
- Headquarters Fort Collins, United States
- Stage Acquired
- SectorsHealthcare
- Website inviragen.com
- Social LinkedIn
- Acquired by Takeda (May 2013)
- Legal Name Inviragen, Inc
Products & Services of Inviragen
Inviragen offers a comprehensive portfolio of products and services, including Keluaran HK and Data HK.
Provides real-time Hong Kong lottery results for users
Aggregates and updates historical lottery data online
Funding Insights of Inviragen
Inviragen has successfully raised a total of $15.31M across 11 strategic funding rounds. The most recent funding activity was a Series B round of $15.31 million completed in January 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $15.31M
- Total Rounds 11
- Last Round Series B — $15.31M
- First Round $2.83M
(Jun 2005)
- Investors Count 4
Latest 10 of 11 funding rounds of Inviragen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2012 | $15.31M | Series B | – | EDBI, Charter Life Sciences | – |
| Sep 2009 | $2.83M | Grant | – | – | |
| Sep 2009 | $599,970 | Grant | – | – | |
| Aug 2009 | $599,970 | Grant | – | – | |
| Sep 2008 | $373,315 | Grant | – | – | |
| Sep 2008 | $427,627 | Grant | – | – | |
| Sep 2008 | $427,627 | Grant | – | – | |
| Aug 2008 | $1.26M | Grant | – | – | |
| Nov 2007 | Grant | – | – | ||
| Sep 2006 | $1.26M | Grant | – | – |
5 investors in total: 5 institutional.
Investors in Inviragen
Inviragen has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include NIH, Takeda Pharmaceuticals and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government-backed investments are directed toward healthcare, fintech, and various sectors. | edbi.com | Singapore, Singapore | ||
| clsvc.com | ||||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
Takeda Pharmaceuticals is engaged in developing innovative medicines globally. | 1781 | takeda.com | Tokyo, Japan |
Investor details for Inviragen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Inviragen
Inviragen has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include SingVax.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Prophylactic vaccines for infectious diseases. | singvax.com | Singapore | 2004 | Oct 2009 | •••• |
Complete acquisition details for Inviragen
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Inviragen
Competitors of Inviragen
Inviragen has 3 listed competitors in our database, 3 of them funded. They include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| adaptivebiotech.com | 2009 | Seattle, United States | $419.15M | 609 | Clinical diagnostics and drug discovery for immune diseases are provided. | |
| generatebiomedicines.com | 2018 | Somerville, United States | $643M | 286 | Developer of novel protein-based therapeutics using machine learning and biological engineering |
Detailed competitors of Inviragen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Inviragen (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Inviragen
Complete news archive for Inviragen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Inviragen
Inviragen was founded in 2005.
Inviragen is headquartered in Fort Collins, United States. It is registered at Fort Collins, Colorado, United States.
Inviragen is a funded company, having raised a total of $15.31M across 11 funding rounds to date. The company's 1st funding round was a Grant of $1.26M, raised on Jun 2005.
Inviragen was founded in 2005 in Fort Collins, United States, focusing on the biotechnology sector. Vaccines were developed there to address infectious diseases such as dengue, hand-foot-and-mouth disease, chikungunya, Japanese encephalitis, influenza, and a combined plaguesmallpox option for biodefense purposes. The company was acquired by Takeda in 2013 for an initial 35 million, with potential additional payments up to 215 million based on development progress and commercial milestones.
Inviragen's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
Inviragen offers Keluaran HK and Data HK.
Inviragen has made 1 acquisition, including SingVax.
Inviragen has 5 investors. Key investors include NIH, Takeda Pharmaceuticals, HHS, EDBI, and Charter Life Sciences.
Inviragen operates through Inviragen, Inc.
Yes. Inviragen was acquired by Takeda in May 2013.